

GENE EXPRESSION CHANGES OF ENERGY METABOLISM REGULATORS IN ADIPOSE TISSUE OF WOMEN WITH GDM

Kleiblova Petra^{1,2,*} • Kleibl Z.¹ • Krejci V.² • Ticha I.¹ • Haluzik M.³

Inst. of Biochemistry and Exp. Oncology¹, Dept. of Obstetrics and Gynecology², 3rd Dept. of Medicine³ 1st Faculty of Medicine, Charles University in Prague and General Faculty Hospital, Czech Republic, *pekleje@lf1.cuni.cz

Gestational diabetes mellitus (GDM):

The condition of glucose intolerance appearing in woman usually in the second trimester of pregnancy with prevalence 5-7% of pregnancies worldwide. GDM is considered to be an independent risk factor for subsequent type 2 diabetes mellitus development.

The AIM of our study was to characterize expression profile of genes participating to the energy metabolism regulations in adipose tissue pre-selected by gene expression array.

Tab.1. Characteristics of 27 study subjects (GDM and healthy nondiabetic women).

All subjects	Number of subjects	BMI before pregnancy Mean <range> [kg/m ²]	BMI 3 rd day after delivery Mean <range> [kg/m ²]	Age Mean [y]
Control group	13	22.7 <19.0-30.5>	25.5 <20.8-32.3>	33.1
GDM	14	28.9 <18.8-38.2>	31.2 <19.9-42.4>	34.1
- GDM-Insulin	9	30.1 <19.7-38.2>	32.9 <19.9-42.4>	34.6
- GDM-Diet	5	26.8 <18.8-35.4>	28.3 <22.0-34.9>	33.2

Tab.2. Subgroups of normal-weight controls (pre-gestational BMI 20-25) and obese diabetic women (pre-gestational BMI>30).

BMI-selected	Number of subjects	BMI before pregnancy Mean <range> [kg/m ²]	BMI 3 rd day after delivery Mean <range> [kg/m ²]	Age Mean [y]
Control group	8	22.4 <20.4-24.8>	25.3 <23.1-28.0>	33.4
GDM	9	33.0 <25.1-38.2>	35.4 <30.9-42.4>	33.2
- GDM-Insulin	7	32.8 <25.1-38.2>	36.1 <30.9-42.4>	33.4
- GDM-Diet	2	33.7 <32.0-35.4>	33.1 <31.2-34.9>	32.5

Fig.1. cRNA array analysis (and corresponding clinical data) of insulin-related signaling pathway in 13 selected subcutaneous and visceral adipose tissue samples of control and GDM women (clustering by MeV software).





Fig.4. Correlation of IRS2 and PRL genes expression assessed by qPCR and arrays in panel of subcutaneous and visceral adipose tissue assessed (relative expression to housekeeping genes).



METHODS:

The women with single pregnancy parturient by Caesarean section were enrolled. All subjects gave the informed consent approved by local ethical committee.

Subcutaneous and visceral (omental) adipose tissue samples were obtained during surgery in 14 women with GDM (9 treated by s.c. insulin and 5 treated by diet regimes) and 13 healthy lean women in control group with physiological pregnancy. Mean age and gestation age at the delivery were comparable in all groups (Tab.1 and 2).

The tissue samples were preserved in RNeasy (Qiagen) in -20°C until total RNA isolation by RNeasy Lipid Tissue Mini Kit (Qiagen) according to manufacturer.

Genes with differential gene expression were identified using gene expression array targeted to 128 genes involving to insulin receptor pathway (Human Insulin Signaling Pathway Microarray; Superarray; Fig. 1) in a group of 5 patients with GDM (3 treated by insulin, 2 by diet regimes) and 3 healthy controls.

Expressions of selected genes (Fig. 2) were analyzed by qPCR using SybrGreen (LightCycler 2.0; Roche) and quantified by REST-384-beta software or qGENE software.

qPCR technical notes:

- All RNA samples were treated by DNase.
- SuperScript III and random hexanucleotides were used for cDNA synthesis.
- qPCR for all genes were optimized for Mg²⁺, annealing temperatures; efficiency (and test sensitivity) were assessed (Fig.3).
- Amplicons specificities were evaluated in each reaction by agarose gel electrophoresis. PCR amplicons using in-house primer sets were sequenced.
- Samples were analyzed in doublets.
- Negative controls were implemented in each run.
- Normalization by REST-384 was performed to 3 house-keepings (B2M, GAPDH and PBGD).




Fig.3. PCR efficiency of all tested genes were estimated based on RNA dilution curves evaluated in REST.

RESULTS:

The most apparent changes in visceral adipose tissue of pregnant women with GDM involved up-regulation of NOS2A mRNA (2.5x; p=0.005) and down-regulation of PRL (10.2x; p=0.024), IRS2 (1.5x; p=0.030), and IGFBP1 (12.6x; p=0.021) comparing to healthy cohort. In the subgroup of pregnant women with GDM treated by insulin down-regulation of PRL was 15x (p=0.008) and IGFBP1 29.7x (p=0.006). Moreover, in subgroup of obese pregnant women with GDM treated by insulin the decrease of PRL (19.3x; p=0.024) and IGFBP1 (33.5x; p=0.018) expression, together with decreased IRS2 (1.9x; p=0.021) expression was found (comparing to healthy controls).

In subcutaneous adipose tissue of GDM patients the 2.1-fold increase of LDLR (p=0.004) was found. Additionally, in a subgroup of pregnant women with GDM treated by insulin the down-regulation of IRS2 (1.8x; p=0.018) was detected.

CONCLUSIONS:

1. This pilot results indicate substantial alteration of gene expression of insulin pathway regulators in GDM patients. Currently running prospective study will score the ability of gene expression profiling for the early diagnostics of the type 2 DM risk development in GDM patients.
2. Using insulin-related pathways arrays another 16 genes differentially expressed in adipose/visceral are currently evaluated (except these reported here). Using a qPCR approach, larger cohort of analyzed individuals was evaluated. The comparison of array and qPCR demonstrates a good correlation of expression analysis results (Fig. 4).
3. Pathogenesis of GDM is influenced by a differential involvement of subcutaneous/visceral adipose tissues.